thiophenes has been researched along with abt-199 in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 7 (35.00) | 24.3611 |
| 2020's | 13 (65.00) | 2.80 |
| Authors | Studies |
|---|---|
| He, S; Li, Z; Look, AT | 1 |
| Chanrion, M; Claperon, A; Colland, F; Geneste, O; Ghiurau, C; Halilovic, E; Huang, D; Ivey, A; Kraus-Berthier, L; Lan, P; Lessene, G; Macraild, S; Maragno, AL; Morris, E; Moujalled, DM; Pomilio, G; Rijal, S; Roberts, AW; Rocchetti, F; Salmon, J; Segal, D; Teh, TC; Tiong, IS; Wang, Y; Wei, AH; Zhang, L; Zichi, A | 1 |
| Bachireddy, P; Brooks, AN; Buonamici, S; Burger, JA; Carrasco, RD; Davids, MS; Deng, J; Ghia, EM; Gill, AL; Gruber, M; Kim, E; Kipps, TJ; Letai, A; Meyerson, ML; Neuberg, D; Rassenti, LZ; Reed, R; Regis, FFD; Seiler, M; Smith, P; Sun, J; Ten Hacken, E; Thomas, M; Valentin, R; Wang, L; Werner, L; Wong, J; Wu, CJ; Yin, S; Zheng, M | 1 |
| Andera, L; Berkova, A; Forsterova, K; Fronkova, E; Havranek, O; Helman, K; Karolova, J; Klanova, M; Klener, P; Nahacka, Z; Pacheco-Blanco, M; Pokorna, E; Prukova, D; Soukup, J; Svaton, M; Svobodova, K; Trneny, M; Tuskova, D; Vockova, P; Zemanova, Z | 1 |
| Algarín, EM; Banquet, S; Corchete, LA; Derreal, A; Díaz-Tejedor, A; Garayoa, M; González-Méndez, L; Gutiérrez, NC; Halilovic, E; Hernández-García, S; Kloos, I; Kraus-Berthier, L; Maacke, H; Martín-Sánchez, M; Mateos, MV; Mogollón, P; Ocio, EM; Paíno, T; San-Segundo, L; Schoumacher, M | 1 |
| Gilmore, A; King, L | 1 |
| Adams, JM; Dengler, MA; Gangoda, L; Gray, DH; Herold, MJ; Kelly, GL; Lan, P; Roberts, AW; Teh, CE; Thijssen, R | 1 |
| Ammatuna, E; de Jong, MRW; Langendonk, M; Nijland, M; Reitsma, B; van den Berg, A; van Meerten, T; Visser, L | 1 |
| Dittmann, J; Ewald, L; Fulda, S; Vogler, M | 1 |
| Chim, CS; Wong, KY | 1 |
| Bierbrauer, A; Fulda, S; Jacob, M; Vogler, M | 1 |
| Belhadj, M; Birsen, R; Bouscary, D; Cantero Aguilar, L; Chapuis, N; Fontenay, M; Grignano, E; Guillonneau, F; Haddaoui, L; Hormi, M; Hunault, M; Huynh, T; Kosmider, O; Mayeux, P; Tamburini, J | 1 |
| Bala Tannan, N; Da Silva Ferreira, M; de Stanchina, E; Hagen, C; Heller, DA; Herviou, L; Kiguchi, H; Manova-Todorova, K; Manzari, MT; Seshan, V; Younes, A | 1 |
| Adamia, S; Bhatt, S; Bohl, SR; Garcia, JS; Halilovic, E; Kim, AS; Kuang, Y; Letai, A; Leutz, B; Louissaint, A; Mashaka, T; Mehta, AK; Mogili, A; Morris, E; Olesinski, EA; Paweletz, CP; Pioso, MS; Ryan, JA; Sanghavi, S; Wang, Y; Weinstock, DM; Yilma, B; Zhu, H | 1 |
| Algarín, EM; Campos-Laborie, FJ; De Las Rivas, J; Díaz-Tejedor, A; Garayoa, M; García-Sanz, R; González-Méndez, L; Gutiérrez, NC; Martín-Sánchez, M; Mogollón, P; Ocio, EM; Paíno, T; Quwaider, D; San-Segundo, L; Vuelta, E | 1 |
| Agostinelli, C; Alcalay, M; Baiardi, E; Bertolini, F; Calleri, A; Casadei, B; Corsini, C; Derenzini, E; Falvo, P; Fiori, S; Mazzara, S; Melle, F; Motta, G; Orecchioni, S; Pelicci, PG; Pileri, S; Rossi, A; Tabanelli, V; Tarella, C; Vitolo, U; Zinzani, PL | 1 |
| Berezovskaya, A; Etchin, J; He, S; Jing, CB; Kaufman, CK; Layden, HM; Look, AT; Mansour, MR; Martel, MW; Patton, EE; Rodig, SJ; Thurston, G; van Rooijen, E; Zimmerman, MW; Zon, LI | 1 |
| Albert, R; Alcon, C; Gómez Tejeda Zañudo, J; Letai, A; Montero, J; Samitier, J; Scaltriti, M; Wagle, N | 1 |
| Bassermann, F; Branca, C; Brockow, K; Buck, MC; Buschhorn, L; Dechant, M; Dill, V; Götze, K; Hauch, RT; Höckendorf, U; Jilg, S; Jost, PJ; Moog, P; Odinius, TO; Reiter, A; Schwaab, J; Shoumariyeh, K; Wagner, C | 1 |
| Gai, Y; Lin, H; Liu, F; Liu, S; Lv, J; Su, Y; Wang, G; Wang, Y; Zhao, Q | 1 |
1 review(s) available for thiophenes and abt-199
| Article | Year |
|---|---|
Emerging approaches to target mitochondrial apoptosis in cancer cells.
Topics: Aniline Compounds; Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bridged Bicyclo Compounds, Heterocyclic; Humans; Mitochondria; Mitochondrial Membrane Transport Proteins; Neoplasms; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2019 |
1 trial(s) available for thiophenes and abt-199
| Article | Year |
|---|---|
Dual targeting of the DNA damage response pathway and BCL-2 in diffuse large B-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Bridged Bicyclo Compounds, Heterocyclic; DNA Repair Enzymes; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression Regulation, Leukemic; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Middle Aged; Prognosis; Prospective Studies; Proto-Oncogene Proteins c-bcl-2; Retrospective Studies; Sulfonamides; Survival Rate; Thiophenes; Urea; Young Adult | 2022 |
18 other study(ies) available for thiophenes and abt-199
| Article | Year |
|---|---|
The MCL1-specific inhibitor S63845 acts synergistically with venetoclax/ABT-199 to induce apoptosis in T-cell acute lymphoblastic leukemia cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Drug Synergism; Embryo, Nonmammalian; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Pyrimidines; Sulfonamides; T-Lymphocytes; Thiophenes; Tumor Cells, Cultured; Zebrafish | 2019 |
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia.
Topics: Animals; Antineoplastic Agents; Biomimetics; Bridged Bicyclo Compounds, Heterocyclic; Drug Therapy, Combination; Female; Humans; Leukemia, Myeloid, Acute; Male; Mice; Mice, Inbred NOD; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2019 |
Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies.
Topics: Adult; Aged; Aged, 80 and over; Alternative Splicing; Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Disease Models, Animal; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epoxy Compounds; Female; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Macrolides; Male; Mice; Mice, Transgenic; Middle Aged; Mitochondria; Mutation; Myeloid Cell Leukemia Sequence 1 Protein; Phosphoproteins; Primary Cell Culture; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; RNA Splicing Factors; Spliceosomes; Sulfonamides; Thiophenes | 2018 |
Cotargeting of BCL2 with Venetoclax and MCL1 with S63845 Is Synthetically Lethal
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Recurrence, Local; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes; Xenograft Model Antitumor Assays | 2019 |
Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma.
Topics: Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Humans; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2020 |
Potent efficacy of MCL-1 inhibitor-based therapies in preclinical models of mantle cell lymphoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cell Proliferation; Humans; Lymphoma, Mantle-Cell; Mice; Mice, Inbred NOD; Mice, SCID; Myeloid Cell Leukemia Sequence 1 Protein; Pyrimidines; Sulfonamides; Thiophenes; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2020 |
Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
Topics: Aniline Compounds; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bcl-2-Like Protein 11; bcl-X Protein; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Survival; Cyclophosphamide; Doxorubicin; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Humans; Lymphoma, Large B-Cell, Diffuse; Myeloid Cell Leukemia Sequence 1 Protein; Prednisone; Prognosis; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Rituximab; Signal Transduction; Sulfonamides; Thiophenes; Treatment Outcome; Vincristine | 2019 |
Side-by-side comparison of BH3-mimetics identifies MCL-1 as a key therapeutic target in AML.
Topics: Adult; Aged; Aged, 80 and over; Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; bcl-2-Associated X Protein; Bridged Bicyclo Compounds, Heterocyclic; Caspases; Cell Line, Tumor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Peptide Fragments; Proto-Oncogene Proteins; Pyrimidines; Sulfonamides; Thiophenes; Young Adult | 2019 |
Venetoclax, bortezomib and S63845, an MCL1 inhibitor, in multiple myeloma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Chromosomes, Human, Pair 11; Chromosomes, Human, Pair 14; Drug Resistance, Neoplasm; Drug Synergism; Humans; Inhibitory Concentration 50; Multiple Myeloma; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes; Translocation, Genetic | 2020 |
A direct comparison of selective BH3-mimetics reveals BCL-X
Topics: Apoptosis; bcl-2 Homologous Antagonist-Killer Protein; Bcl-2-Like Protein 11; bcl-X Protein; Biomimetics; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; Humans; Myeloid Cell Leukemia Sequence 1 Protein; Neuroblastoma; Peptide Fragments; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2020 |
Pairing MCL-1 inhibition with venetoclax improves therapeutic efficiency of BH3-mimetics in AML.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cells, Cultured; Coculture Techniques; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Mesenchymal Stem Cells; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2020 |
Tumor-targeted nanoparticles improve the therapeutic index of BCL2 and MCL1 dual inhibition.
Topics: Animals; Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Carriers; Drug Delivery Systems; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Mice; Myeloid Cell Leukemia Sequence 1 Protein; Nanoparticles; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Therapeutic Index; Thiophenes | 2021 |
Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia.
Topics: Animals; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Humans; Leukemia, Myeloid, Acute; Mice; Mitochondria; Peptide Fragments; Proto-Oncogene Proteins; Pyrimidines; Signal Transduction; Sulfonamides; Thiophenes | 2020 |
Stroma-Mediated Resistance to S63845 and Venetoclax through MCL-1 and BCL-2 Expression Changes Induced by miR-193b-3p and miR-21-5p Dysregulation in Multiple Myeloma.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Drug Resistance, Neoplasm; Humans; Multiple Myeloma; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2021 |
Synergistic melanoma cell death mediated by inhibition of both MCL1 and BCL2 in high-risk tumors driven by NF1/PTEN loss.
Topics: Animals; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Everolimus; Humans; Loss of Function Mutation; Melanoma; MTOR Inhibitors; Myeloid Cell Leukemia Sequence 1 Protein; Neurofibromin 1; Proto-Oncogene Proteins c-bcl-2; PTEN Phosphohydrolase; Pyrimidines; Sirolimus; Sulfonamides; Thiophenes; Xenograft Model Antitumor Assays; Zebrafish | 2021 |
ER+ Breast Cancer Strongly Depends on MCL-1 and BCL-xL Anti-Apoptotic Proteins.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; bcl-X Protein; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Drug Resistance, Neoplasm; Drug Synergism; Estrogen Receptor alpha; Everolimus; Female; Fulvestrant; Gene Expression Regulation, Neoplastic; Humans; MCF-7 Cells; Myeloid Cell Leukemia Sequence 1 Protein; Piperazines; Protein Isoforms; Proto-Oncogene Proteins c-akt; Pyridines; Pyrimidines; Signal Transduction; Sulfonamides; Thiazoles; Thiophenes | 2021 |
Comprehensive characterization of central BCL-2 family members in aberrant eosinophils and their impact on therapeutic strategies.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Bcl-2-Like Protein 11; Bridged Bicyclo Compounds, Heterocyclic; Case-Control Studies; Cells, Cultured; Eosinophilia; Eosinophils; Granulomatosis with Polyangiitis; HL-60 Cells; Humans; Hypereosinophilic Syndrome; Myeloproliferative Disorders; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2022 |
Cotargeting of Bcl-2 and Mcl-1 shows promising antileukemic activity against AML cells including those with acquired cytarabine resistance.
Topics: Antineoplastic Agents; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cytarabine; Drug Resistance, Neoplasm; Drug Synergism; Humans; Leukemia, Myeloid, Acute; Molecular Targeted Therapy; Myeloid Cell Leukemia Sequence 1 Protein; Proto-Oncogene Proteins c-bcl-2; Pyrimidines; Sulfonamides; Thiophenes | 2022 |